Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2016

  • ID: 3775428
  • Drug Pipelines
  • 50 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Alligator Bioscience AB
  • Apogenix GmbH
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • MedImmune, LLC
  • Pfizer Inc.
  • MORE
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2016

Summary

‘Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) targeted pipeline therapeutics.

The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Alligator Bioscience AB
  • Apogenix GmbH
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • MedImmune, LLC
  • Pfizer Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Overview

Therapeutics Development

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Products under Development by Stage of Development

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Products under Development by Therapy Area

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Products under Development by Indication

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Pipeline Products Glance

Early Stage Products

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Products under Development by Companies

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development

Alligator Bioscience AB

Apogenix GmbH

BioInvent International AB

Bristol-Myers Squibb Company

Enumeral Biomedical Holdings, Inc.

Genentech, Inc.

GlaxoSmithKline Plc

MedImmune, LLC

Pfizer Inc.

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Drug Profiles

ADC-1015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Delta-24-RGDOX - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + MEDI-6383 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3174998 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-0562 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-6383 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-04518600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize OX40 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Agonize OX40 and Notch 3 for Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Dormant Projects

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Discontinued Products

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) - Featured News & Press Releases

Nov 03, 2015: GSK and Merck to study immunotherapy combination as potential cancer treatment

Oct 20, 2014: AgonOx’s OX40 Platform Being Utilized in MedImmune’s Phase 1 OX40 Agonist Study

Sep 21, 2011: AgonOx Receives US Patent For OX40 Ligand Fusion Proteins And Use In Cancer Therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Alligator Bioscience AB, H1 2016

Pipeline by Apogenix GmbH, H1 2016

Pipeline by BioInvent International AB, H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by Enumeral Biomedical Holdings, Inc., H1 2016

Pipeline by Genentech, Inc., H1 2016

Pipeline by GlaxoSmithKline Plc, H1 2016

Pipeline by MedImmune, LLC, H1 2016

Pipeline by Pfizer Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Alligator Bioscience AB
  • Apogenix GmbH
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • MedImmune, LLC
  • Pfizer Inc.
  • MORE
According to our recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 4 – Pipeline Review, H1 2016'; Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies.

Furthermore, the publisher says; Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions.

The report 'Tumor Necrosis Factor Receptor Superfamily Member 4 – Pipeline Review, H1 2016' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase I, Preclinical and Discovery stages are 6, 5 and 2 respectively.
Note: Product cover images may vary from those shown
5 of 6
Alligator Bioscience AB
Apogenix GmbH
BioInvent International AB
Bristol-Myers Squibb Company
Enumeral Biomedical Holdings, Inc.
Genentech, Inc.
GlaxoSmithKline Plc
MedImmune, LLC
Pfizer Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll